Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (The FASE Study)

Gynecologic Oncology

Volumn 125, Issue 1, 2012, Pages 175-180

  Monsonego, Joseph ^a   Hudgens, Michael G ^b   Zerat, Laurent ^c   Zerat, Jean Claude ^c   Syrjänen, Kari ^d   Smith, Jennifer S ^b  

^a Institute of the Cervix   (France)

^b IL   (United States)

^c Laboratoire Lavergne   (France)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Absolute risk; Cervical cancer screening; CIN gold standards; HPV DNA test; HPV RNA test; Relative risk

Indexed keywords

MESSENGER RNA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASSAY; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC TEST; DNA TUMOR VIRUS; FEMALE; FOOD AND DRUG ADMINISTRATION; FRANCE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS ASSAY; HYBRID CAPTURE 2; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VALIDATION STUDY; VIRUS CULTURE; WART VIRUS;

ADULT; AGED; ALPHAPAPILLOMAVIRUS; COLPOSCOPY; CROSS-SECTIONAL STUDIES; CYTODIAGNOSIS; DNA PROBES, HPV; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84862777021     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.01.002     Document Type: Article

References (43)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] 2010 International Agency for Research on Cancer Lyon, France Available from http://globocan.iarc.fr
2. A.B. Miller, S. Nazeer, S. Fonn, A. Brandup-Lukanow, R. Rehman, and H. Cronje Report on consensus conference on cervical cancer screening and management Int J Cancer 86 2000 440 447 (Pubitemid 30187509)
3. K.J. Syrjänen, I.P. Shabalova, O. Ivanchenko, L.B. Kljukina, V. Grunberga, and S.M. Syrjänen Reproducibility of classification and correction for verification bias as determinants of performance of Papanicolaou smear cytology in the screening setting: experience from the New Independent States of the former Soviet Union cohort study Acta Cytol 53 2009 548 557
4. Haute Autorité de Santé Cancer du col de l'utérus. Press release, November 15, 2010 Available from http://www.has-sante.fr/portail/ jcms/c-998815/cancer-du-col-de-luterus
5. D. Solomon, M. Schiffman, R. Tarone ALTS Study group Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial J Natl Cancer Inst 93 2001 293 299 (Pubitemid 32219816)
6. M.H. Stoler, and M. Schiffman Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study JAMA 285 2001 1500 1505 (Pubitemid 32221899)
7. J. Monsonego, A. Autillo-Touati, C. Bergeron, R. Dachez, J. Liaras, and J. Saurel Liquid-based cytology for primary cervical cancer screening: a multi-centre study Br J Cancer 84 2001 360 366 (Pubitemid 32154429)
8. M. Arbyn, C. Bergeron, P. Klinkhamer, P. Martin-Hirsch, A.G. Siebers, and J. Bulten Liquid compared with conventional cervical cytology: a systematic review and meta-analysis Obstet Gynecol 111 2008 167 177
9. H. zur Hausen Papillomaviruses in the causation of human cancers-a brief historical account Virology 384 2009 260 265
10. M. Arbyn, F. Buntinx, M. Van Ranst, E. Paraskevaidis, P. Martin-Hirsch, and J. Dillner Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia J Natl Cancer Inst 96 2004 280 293 (Pubitemid 38256273)
11. G. Ronco, P. Giorgi-Rossi, F. Carozzi, M. Confortini, P. Dalla Palma, and A. Del Mistro New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papilloma testing for the detection of invasive cervical cancers and cervical epithelial neoplasia: a randomized controlled trial Lancet Oncol 11 2010 249 257
12. J. Cuzick, A. Szarewski, D. Mesher, L. Cadman, J. Austin, and K. Perryman Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-results from the Hammersmith study Int J Cancer 122 2008 2294 2300 (Pubitemid 351542334)
13. J. Dillner, M. Rebolj, P. Birembaut, K.U. Petry, A. Szarewski, and C. Munk Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study BMJ 337 2008 a1754
14. J.F. Shi, J.L. Belinson, F.H. Zhao, R.G. Pretorius, J. Li, and J.F. Ma Human papillomavirus testing for cervical cancer screening: results from a 6-year prospective study in rural China Am J Epidemiol 170 2009 708 716
15. M.H. Mayrand, E. Duarte-Franco, I. Rodrigues, S.D. Walter, J. Hanley, and A. Ferenczy Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer N Engl J Med 357 2007 1579 1588 (Pubitemid 47598400)
16. G. Ronco, P. Giorgi-Rossi, F. Carozzi, M. Confortini, P.P. Dalla, and M.A. Del Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test J Natl Cancer Inst 100 2008 492 501
17. J.G. Baseman, S.L. Kulasingam, T.G. Harris, J.P. Hughes, N.B. Kiviat, and C. Mao Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States Am J Obstet Gynecol 199 2008 26 28
18. S.L. Kulasingam, J.P. Hughes, N.B. Kiviat, C. Mao, N.S. Weiss, and J.M. Kuypers Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral JAMA 288 2002 1749 1757
19. P. Sasieni, A. Castanon, and D.M. Parkin How many cervical cancers are prevented by treatment of screen-detected disease in young women? Int J Cancer 124 2009 461 464
20. P.K. Chan, A.R. Chang, M.Y. Yu, W.H. Li, M.Y. Chan, and A.C. Yeung Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies Int J Cancer 126 2010 297 301
21. J. Cuzick, M. Arbyn, R. Sankaranarayanan, V. Tsu, G. Ronco, and M.H. Mayrand Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries Vaccine 26 2008 K29 K41
22. K. Syrjänen, S. Derchain, C. Roteli-Martins, A. Longatto-Filho, L.S. Hammes, and L. Sarian Value of conventional pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among Latin American women < 35 and > or = 35 years of age: experience from the Latin American Screening Study Acta Cytol 52 2008 641 653
23. M. Quinn, P. Babb, J. Jones, and E. Allen Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics BMJ 318 1999 904 908 (Pubitemid 29191925)
24. P. Sasieni, J. Adams, and J. Cuzick Benefit of cervical screening at different ages: evidence from the UK audit of screening histories Br J Cancer 89 2003 88 93 (Pubitemid 36897941)
25. M. Arbyn, P. Sasieni, C.J.L.M. Meijer, C. Clavel, G. Koliopoulos, and J. Dillner Chapter 9: clinical applications of HPV testing: a summary of meta-analyses Vaccine 24S3 2006 78 89
26. T. Molden, I. Kraus, H. Skomedal, T. Nordstrom, and F. Karlsen PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses J Virol Methods 142 2007 204 212 (Pubitemid 46590424)
27. P.E. Castle, J. Dockter, C. Giachetti, F.A. Garcia, M.K. McCormick, and A.L. Mitchell A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer Clin Cancer Res 13 2007 2599 2605 (Pubitemid 46788025)
28. J. Dockter, A. Schroder, B. Eaton, A. Wang, N. Sikhamsay, and L. Morales Analytical characterization of the APTIMA HPV assay J Clin Virol 45 Suppl 1 2009 S39 S47
29. J. Dockter, A. Schroder, C. Hill, L. Guzenski, J. Monsonego, and C. Giachetti Clinical performance of the APTIMA HPV assay for the detection of high-risk HPV and high-grade cervical lesions J Clin Virol 45 Suppl 1 2009 S55 S61
30. M. Waldstrom, and D. Ornskov Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US) Cytopathology 19 2011 doi: 10.1111/j.1365-2303.2011.00923.x. [Epub ahead of print]
31. A. Szarewski, L. Ambroisine, L. Cadman, J. Austin, L. Ho, and G. Terry Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears Cancer Epidemiol Biomarkers Prev 17 2008 3033 3042
32. D. Getman, A. Aiyer, J. Dockter, C. Giachetti, F. Zhang, and C.C. Ginocchio Efficiency of the APTIMA HPV assay for detection of HPV RNA and DNA targets J Clin Virol 45 Suppl 1 2009 S49 S54
33. J. Monsonego, M.G. Hudgens, L. Zerat, J.-C. Zerat, K. Syrjänen, and P. Halfon Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study Int J Cancer 129 2011 691 701
34. P.E. Castle, D. Solomon, C.M. Wheeler, P.E. Gravitt, S. Wacholder, and M. Schiffman Human papillomavirus genotype specificity of hybrid capture 2 J Clin Microbiol 46 2008 2595 2604
35. Gen-Probe APTIMA® HPV Assay [package insert] 2008 Gen-Probe Inc San Diego, Calif
36. A. Söderlund-Strand, J. Carlson, and J. Dillner Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus J Clin Microbiol 47 2009 541 546
37. R. Flores-Munguia, E. Siegel, W.T. Klimecki, and A.R. Giuliano Performance assessment of eight high-throughput PCR assays for viral load quantitation of oncogenic HPV types Mol Diagn 6 2004 115 124 (Pubitemid 38578987)
38. M. Lindh, S. Görander, E. Andersson, P. Horal, I. Mattsby-Balzer, and W. Ryd (4) Real-time Taqman PCR targeting 14 human papilloma virus types J Clin Virol 40 2007 321 324 (Pubitemid 350152007)
39. P. Walker, S. Dexeus, G. De Palo, R. Barrasso, M. Campion, and F. Girardi Nomenclature Committee of the International Federation for Cervical Pathology and Colposcopy. International terminology of colposcopy: an updated report from the International Federation for Cervical Pathology and Colposcopy Obstet Gynecol 101 2003 175 177 (Pubitemid 36057105)
40. P.T. Seed, and A. Tobias Summary statistics for diagnostic tests Stata Techn Bull 59 2001 9 12
41. R. Zuna, S.S. Wang, M. Schiffman, D. Solomon for the ALTS study group Comparison of human papillomavirus distribution in cytological subgroups of low-grade squamous intraepithelial lesion Cancer Cytopathol 108 2006 288 297 (Pubitemid 44583707)
42. G. Koliopoulos, M. Arbyn, P. Martin-Hirsch, M. Kyrgiou, W. Prendiville, and E. Paraskevaidis Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies Gynecol Oncol 104 2007 232 246 (Pubitemid 46054137)
43. J. Monsonego, G. Pollini, M.J. Evrard, P. Sednaoui, L. Monfort, and D. Quinzat Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear Int J STD AIDS 19 2008 385 392